NOS2 and myeloproliferative disorder: Hydroxyurea (HU) is a ribonucleotide reductase inhibitor widely used for the treatment of sickle cell disease and myeloproliferative disorders, yet a precise nitric oxide (NO) synthase (NOS)-dependent mechanism remains incompletely defined.